同和药业(300636.SZ)：甲苯磺酸艾多沙班原料药通过CDE审批

Core Viewpoint - Tonghua Shunhe Pharmaceutical has received approval from the CDE for its raw material drug "Tafluprost Tosylate," which is an oral anticoagulant used primarily for preventing strokes and systemic embolism in patients with non-valvular atrial fibrillation, as well as for the treatment or prevention of deep vein thrombosis and pulmonary embolism [1] Group 1 - The drug "Tafluprost Tosylate" is indicated for the prevention of strokes in non-valvular atrial fibrillation patients [1] - The drug is also used for the treatment or prevention of deep vein thrombosis and pulmonary embolism [1]